Previous Article | Next Article 
Journal of Clinical Microbiology, August 2008, p. 2774-2777, Vol. 46, No. 8
0095-1137/08/$08.00+0 doi:10.1128/JCM.00460-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Recovery of Herbaspirillum Species from Persons with Cystic Fibrosis
Theodore Spilker,1
Ahmet Z. Uluer,2
Francisco M. Marty,3
Wendy W. Yeh,3
Julie H. Levison,3
Peter Vandamme,4 and
John J. LiPuma1*
Division of Infectious Diseases, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan,1
Adult Cystic Fibrosis Program, Brigham and Women's Hospital and Children's Hospital, Boston, Massachusetts,2
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts,3
Laboratorium voor Microbiologie, Universiteit Gent, Ghent, Belgium4
Received 7 March 2008/
Returned for modification 8 May 2008/
Accepted 25 May 2008

ABSTRACT
Herbaspirillum species are not known to be human pathogens.
We report on the identification of
Herbaspirillum from cultures
from 28 persons with cystic fibrosis (CF). Most isolates were
initially identified as members of the
Burkholderia cepacia complex. Although the role that these species play in lung disease
in persons with CF is not known, their differentiation from
other species is important and has serious implications for
clinical care and patient well-being.

TEXT
Cystic fibrosis (CF), which results from mutations in the cystic
fibrosis transmembrane conductance regulator, is characterized
by multiorgan dysfunction and a predisposition to chronic infection
of the respiratory tract. Although bacteria pathogenic for humans,
such as
Staphylococcus aureus and
Haemophilus influenzae, are
important in respiratory tract infections in persons with CF,
particularly among young patients, a variety of opportunistic
human pathogens also play a role in lung disease in persons
with CF. Among these,
Pseudomonas aeruginosa is the most important,
infecting

80% of adult patients with CF. Other species, such
as members of the
Burkholderia cepacia complex,
Stenotrophomonas maltophilia, and
Achromobacter xylosoxidans, are less commonly
found but may be associated with accelerated lung disease and
poor outcomes in persons with CF. Advances in bacterial taxonomy
and genetics-based identification methodologies have led to
a growing appreciation that a variety of other species may also
be recovered from the respiratory tract of persons with CF.
Since January 2000, we have identified Herbaspirillum species in cultures of specimens obtained from multiple CF patients, including a recent isolate recovered from a culture of blood. We present the latter case, describe our experience with identifying Herbaspirillum from other CF patients, and discuss the implications of the correct identification of these species in this patient population.
Case report.
A 26-year-old man with CF characterized by moderate to severe lung disease, pancreatic insufficiency, diabetes, and liver disease had been stable until 2006, when he required multiple hospital admissions for exacerbations of respiratory symptoms. He received several courses of intravenous antibiotics, but the recovery of pulmonary function became progressively less, as noted on spirometry, until he ultimately required 1 liter of supplemental oxygen via a nasal cannula at night. He was admitted to the hospital in late 2007 for a mild exacerbation of lung disease. A culture of sputum was positive for methicillin-resistant Staphylococcus aureus and mucoid Pseudomonas aeruginosa, for which he was treated with intravenous vancomycin, piperacillin-tazobactam, and tobramycin. His forced expiratory volume in the first second improved, and antibiotics were discontinued after 20 days. However, on hospital day 23, he developed fevers and rigors, and two sets of aerobic cultures of blood drawn on consecutive days were positive for a gram-negative rod, initially identified as belonging to the Burkholderia cepacia complex. On the basis of in vitro susceptibility testing of the recovered bacteria, the antibiotic regimen was changed to intravenous ceftazidime and tobramycin and oral trimethoprim-sulfamethoxazole (TMP-SMX), levofloxacin, and minocycline. His catheter (Port-A-Cath) was removed, he defervesced, and repeat cultures of blood and sputum samples were negative. After 4 weeks of treatment with multiple antibiotics, he was discharged to home to complete a prolonged course of oral TMP-SMX. Analysis of the complete 16S rRNA gene sequences of the blood culture isolates recovered demonstrated a similarity level of 99.9% with sequences of Herbaspirillum species found in the NCBI database (http://www.ncbi.nlm.nih.gov); the level of similarity to Herbaspirillum putei type strain ATCC BAA-806 was 99.6%.
Between January 2000 and December 2007, the Burkholderia cepacia Research Laboratory and Repository (BcRLR; University of Michigan, Ann Arbor) identified Herbaspirillum species from among the isolates recovered from 28 CF patients, including the patient described above. The isolates had been referred for evaluation from 23 CF treatment centers in the United States. The referring laboratories had used a variety of commercial test systems in their initial evaluation of these isolates, which identified 19 (68%) of 28 of the isolates as members of the Burkholderia cepacia complex; 4 (14%) were identified as Ralstonia species, and the remaining 5 (18%) were not identified to the species level (Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1. Putative species identification and phenotypic test systems used by referring laboratories and growth of Herbaspirillum isolates on BCSA
|
Evaluation of the isolates at BcRLR showed variable growth on
B. cepacia selective agar (BCSA [
4]), with most (78%) showing
good to moderate growth on this selective medium (Table
1).
All isolates were grown aerobically on Mueller-Hinton broth
(Becton Dickinson, Cockeysville, MD) supplemented with 1.6%
(wt/vol) agar and were incubated at 32°C for 24 to 48 h.
DNA was prepared from the bacterial cultures as described previously
(
12). A 16S rRNA-targeted PCR assay specific for all
Burkholderia,
Ralstonia, and
Pandoraea species was performed as described
previously (
9); and the results were negative for all 28 isolates.
Previously published 16S rRNA-directed PCR assays specific for
other CF-related bacterial species, including
Pseudomonas,
Stenotrophomonas,
and
Achromobacter (
10,
12,
14,
15), were also negative. Complete
16S rRNA-targeted PCR amplification, sequencing, and editing
were performed as described previously (
12). The edited and
assembled sequences were compared to those available in the
NCBI GenBank bacterial DNA database. The isolates were identified
as
Herbaspirillum species (i.e., to the genus level) if the
identities of the 16S rRNA sequence to the 16S rRNA sequences
of the
Herbaspirillum species in the database were greater then
95%; isolates were tentatively identified to the species level
if the identity was 99.5% or greater to
Herbaspirillum reference
strains available in the database, which included
Herbaspirillum rubrisubalbicans ATCC 19308
T,
Herbaspirillum seropedicae ATCC
35892
T,
H. putei ATCC BAA-806
T,
Herbaspirillum huttiense ATCC
14670
T, and
Herbaspirillum frisingense DSM 13128
T. On the basis
of that analysis, we identified three isolates as
H. huttiense,
three as
H. frisingense, two as
H. seropedicae, and two as
H. putei. Eighteen isolates could not be assigned to a specific
Herbaspirillum species; these appeared to represent at least
three distinct lineages. The first lineage included 14 isolates
whose 16S rRNA sequences shared >99% similarity with those
of the
H. huttiense and
H. putei type strains (Fig.
1). The
other two lineages each comprised a single strain and appeared
to represent novel
Herbaspirillum species. Further taxonomic
work is required to elucidate the taxonomic status of all of
these isolates.
Herbaspirillum species are gram-negative, motile, nitrogen-fixing
bacteria belonging to the class
Betaproteobacteria (
1). They
include pathogens and endophytes of various plants, including
corn, wheat, rice, sugarcane, sorghum, banana, and pineapple
(
1,
3,
11). The genus currently consists of 10 named species:
Herbaspirillum autotrophicum,
Herbaspirillum chlorophenolicum,
H. frisingense,
Herbaspirillum hiltneri,
Herbaspirillum huttiense,
Herbaspirillum lusitanum,
H. putei,
Herbaspirillum rhizosphaerae,
H. rubrisubalbicans, and
H. seropedicae. These species are not
known to be human pathogens. Only a single case of human infection
due to
Herbaspirillum has been described in detail (
13). This
involved bacteremia and cellulitis due to
H. seropedicae in
a 49-year-old homeless man with cirrhosis.
Herbaspirillum has
been reported, however, to have been recovered from various
human sources, including wounds, the respiratory tract, gastric
juice, feces, urine, eye and ear samples, and cases of otitis
and bacteremia (
2). Most of these isolates were not identified
to the species level; rather, similar to most of the isolates
that we report on, these appeared to occupy a novel taxon within
this genus. These isolates, as well as ours and several additional
Herbaspirillum isolates from Canada, Germany, Italy, Switzerland,
and the United Kingdom, are currently undergoing comprehensive
polyphasic characterization to clarify their taxonomic status.
The frequency with which Herbaspirillum species are involved in pulmonary infection in persons with CF is not clear. During the 8-year interval of our study, we analyzed isolates from sputum from greater than 1,100 CF patients, finding Herbaspirillum in only 28 patients (<3%). Although this rate of recovery is comparable to that of some other recognized CF pathogens, such as certain B. cepacia complex species, conclusions regarding the frequency of Herbaspirillum infection in persons with CF are limited in our study by bias in the sample set (i.e., care centers are more likely to refer for analysis "atypical" isolates for which species identification may be in question). We confirmed the presence of other, more common CF-related pathogens, including Achromobacter, Ralstonia, Burkholderia, and Stenotrophomonas, in only 3 (11%) of the 28 patients. This raises the possibility that the recovery of Herbaspirillum may be influenced by the presence of other species that might overgrow Herbaspirillum in mixed cultures. Again, however, a prospective study of a nonbiased sample set is necessary to draw firm conclusions regarding the frequency of Herbaspirillum in persons with CF.
The role that Herbaspirillum species may play in the progression of pulmonary disease in persons with CF is also not clear. The 28 Herbaspirillum-infected patients ranged in age from 20 months to 59 years; the median age at the time of the positive culture was 17 years. For 27 of the 28 patients, we identified only a single Herbaspirillum isolate among the isolates serially obtained from cultures of sputum, suggesting transient colonization with Herbaspirillum. However, chronic infection is possible; in one patient, analysis of serial isolates demonstrated the presence of the same Herbaspirillum strain for 3 years.
Our analysis demonstrates a failure of commercially available microbial identification systems to identify Herbaspirillum species. None of the 28 isolates were identified as Herbaspirillum by the referring laboratories; 85% were initially identified as another opportunistic species more commonly found in cultures of sputum from persons with CF. Misidentification of Herbaspirillum as Burkholderia was particularly common and was likely due to the close phylogenetic and phenotypic relatedness of the species within these genera (Table 2). The failure of commercial test systems to identify Herbaspirillum and the similarity of the phenotypic profile of Herbaspirillum species with those of other CF-related pathogens supports the use of genetics-based methods for the identification of these species.
The misidentification of
Herbaspirillum as
Burkholderia can
have serious consequences for CF patients. Most
Burkholderia strains exhibit constitutive and inducible resistance to the
available antimicrobial agents, and infection is generally refractory
to therapy (
7). Strict infection control policies are recommended
to segregate persons infected with
B. cepacia complex species
from other CF patients in order to reduce the risk of the interpatient
spread of
Burkholderia (
6). These measures place an enormous
psychosocial burden on the patient, as well as a considerable
economic burden on treatment centers. The poor prognosis associated
with
Burkholderia infection is a further source of anxiety for
CF patients, their families, and caregivers. Perhaps most importantly,
due to the particularly poor outcomes after lung transplantation
among persons infected with
Burkholderia, many treatment centers
consider
Burkholderia infection an absolute contraindication
to transplantation, thus denying patients with end-stage pulmonary
disease the only option for survival (
5).
In summary, we identified Herbaspirillum in cultures of sputum from several CF patients. Initial phenotypic evaluation identified none as Herbaspirillum; differentiation from other CF-related pathogens required genetics-based analyses. Most patients appeared to have had transient respiratory tract colonization with Herbaspirillum; however, bacteremia in one patient and a chronic (3-year) respiratory tract infection in another were observed. Although the role that Herbaspirillum may play in contributing to lung diseases in persons with CF requires further study, misidentification of these species, particularly as Burkholderia, has serious implications for clinical care and patient well-being.
Nucleotide sequence accession numbers.
All 16S rRNA gene sequences determined in this study were deposited in the NCBI GenBank database under accession numbers EU549832 through EU549859.

ACKNOWLEDGMENTS
This work was supported by the Cystic Fibrosis Foundation (United
States).
We are indebted to the patients with CF, their families, and the CF care centers, without whose commitment to CF research this report would not have been possible. The authors acknowledge the encouragement and impetus for this report provided by Vincent LaBombardi.
None of the authors has financial interests to declare.

FOOTNOTES
* Corresponding author. Mailing address: Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, 8323 MSRB III, SPC 5646, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0646. Phone: (734) 936-9767. Fax: (734) 764-4279. E-mail:
jlipuma{at}umich.edu 
Published ahead of print on 4 June 2008. 

REFERENCES
1 - Baldani, J. I., V. L. D. Baldani, L. Seldin, and J. Döbereiner. 1986. Characterization of Herbaspirillum seropedicae gen. nov., sp. nov., a root-associated nitrogen fixing bacterium. Int. J. Syst. Bacteriol. 36:86-93.[Abstract/Free Full Text]
2 - Baldani, J. I., B. Pot, G. Kirchhof, E. Falsen, V. L. Baldani, F. L. Olivares, B. Hoste, K. Kersters, A. Hartmann, M. Gillis, and J. Döbereiner. 1996. Emended description of Herbaspirillum; inclusion of [Pseudomonas] rubrisubalbicans, a mild plant pathogen, as Herbaspirillum rubrisubalbicans comb. nov.; and classification of a group of clinical isolates (EF group 1) as Herbaspirillum species 3. Int. J. Syst. Bacteriol. 46:802-810.[Abstract/Free Full Text]
3 - Cruz, L. M., E. M. DeSouza, O. B. Weber, J. I. Baldani, J. Döbereiner, and F. D. Pedrosa. 2001. 16S ribosomal DNA characterization of nitrogen-fixing bacteria isolated from banana (Musa spp.) and pineapple (Ananas comosus (L. Merril). Appl. Environ. Microbiol. 67:2375-2379.[Abstract/Free Full Text]
4 - Henry, D. A., M. E. Campbell, J. J. LiPuma, and D. P. Speert. 1997. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J. Clin. Microbiol. 35:614-619.[Abstract]
5 - LiPuma, J. J. 2001. Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis? Transpl. Infect. Dis. 3:149-160.[CrossRef][Medline]
6 - LiPuma, J. J. 1998. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr. Opin. Pulm. Med. 4:337-341.[CrossRef][Medline]
7 - LiPuma, J. J. 2007. Update on Burkholderia nomenclature and resistance. Clin. Microbiol. Newsl. 29:65-69.[CrossRef]
8 - LiPuma, J. J., B. J. Currie, G. D. Lum, and P. A. R. Vandamme. 2007. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia, and Acidovorax, p. 749-769. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.) Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
9 - LiPuma, J. J., B. J. Dulaney, J. D. McMenamin, P. W. Whitby, T. L. Stull, T. Coenye, and P. Vandamme. 1999. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J. Clin. Microbiol. 37:3167-3170.[Abstract/Free Full Text]
10 - Liu, L., T. Coenye, J. L. Burns, P. W. Whitby, T. L. Stull, and J. J. LiPuma. 2002. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J. Clin. Microbiol. 40:1210-1213.[Abstract/Free Full Text]
11 - Olivares, F. L., V. L. D. Baldani, V. M. Reis, J. I. Baldani, and J. Döbereiner. 1996. Occurrence of the endophytic diazotrophs Herbaspirillum spp. in roots, stems, and leaves, predominantly of Gramineae. Biol. Fertil. Soils 21:197-200.[CrossRef]
12 - Spilker, T., T. Coenye, P. Vandamme, and J. J. LiPuma. 2004. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J. Clin. Microbiol. 42:2074-2079.[Abstract/Free Full Text]
13 - Tan, M., and R. Oehler. 2005. Lower extremity cellulitis and bacteremia with Herbaspirillum seropedicae associated with aquatic exposure in a patient with cirrhosis. Infect. Dis. Clin. Pract. 13:277-279.[CrossRef]
14 - Whitby, P. W., K. B. Carter, J. L. Burns, J. A. Royall, J. J. LiPuma, and T. L. Stull. 2000. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J. Clin. Microbiol. 38:4305-4309.[Abstract/Free Full Text]
15 - Whitby, P. W., K. B. Carter, K. L. Hatter, J. J. LiPuma, and T. L. Stull. 2000. Identification of members of the Burkholderia cepacia complex by species-specific PCR. J. Clin. Microbiol. 38:2962-2965.[Abstract/Free Full Text]
Journal of Clinical Microbiology, August 2008, p. 2774-2777, Vol. 46, No. 8
0095-1137/08/$08.00+0 doi:10.1128/JCM.00460-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.